ADCETRIS™ (brentuximab vedotin), a new CD30-directed antibody-drug conjugate (ADC), was approved by the U.S. Food and Drug Administration (FDA) on August 19, 2011, for the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least 2 prior multiagent chemotherapy regimens. ADCETRIS is also indicated for the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least 1 prior multiagent chemotherapy regimen.1
